Blessie Elizabeth Nelson MD, DMRT
@BlessieNelson
Followers
246
Following
493
Media
24
Statuses
457
Assistant Professor, General & Breast Medical Oncology & Investigational Cancer Therapeutics | MD Anderson | Early Phase Trials & Multimodal Precision Oncology
Joined April 2022
What a beautiful place. And amazing oncology work being done in Norway.
1
2
16
⭐️Huge congrats to the brilliant & amazing @StevenLin_MDPhD and team on their stunning new @Nature paper! From @MDAndersonNews with @adam_grippin: SARS-CoV-2 mRNA vaccines sensitize tumors to immune checkpoint blockade. Nature! Wow!
3
12
58
@BlessieNelson @MDAndersonNews @CCR_AACR @FilipJankuMD @DavidHongMD @rahulshethmd @sarina Congratulations!
0
1
2
Pleased to share results of the long awaited Phase Ib Study of Pembrolizumab with Intratumoral Clostridium novyi-NT in Patients with Advanced Solid Tumors published in CCR https://t.co/sLvG6TjCkI
@MDAndersonNews @CCR_AACR @FilipJankuMD @DavidHongMD @rahulshethmd @Sarina Piha-Paul
2
0
3
Excited to share news of my promotion to Associate Prof in #RadOnc. I have been blessed as junior faculty with both senior & peer mentors who have given me opportunities, feedback, encouragement, & support over the past 6 yrs. Excited to see what the future holds @MDAndersonNews.
42
7
266
⭐️For your Sunday reading: Our @JCOGO_ASCO @ASCO @JCO_ASCO paper reveals precision oncology's harsh reality -life-saving personalized cancer treatments exist but remain out of reach for most patients globally due to policy failures & economic barriers. Time to bridge this gap.
3
24
69
#Myeloma Paper of the Day: Sequential treatment with two different commercially approved BCMA CAR-T products (ide-cel -> cilta-cel) is both feasible and effective, particularly in patients with prolonged responses to initial BCMA CAR-T therapy: https://t.co/dhSt4F2s57.
#mmsm
2
11
43
Highly successful first day getting acclimated in Italy making my way to the GRC Cancer Genetics & Epigenetics Meeting! 🇻🇦🇮🇹
3
3
63
@VJOncology @BlessieNelson @MDAndersonNews @AACR Excellent speech on mutations… Keep going to achieve many in your field.
0
1
1
🎥@BlessieNelson from @MDAndersonNews shares AACR Project GENIE data on metaplastic #breastcancer: high frequency of targetable mutations (TP53, PIK3CA), copy number changes, and mutual exclusivity patterns support precision therapy: ➡️ https://t.co/k3TnfeWvFu⬅️
@AACR #BCSM
vjoncology.com
Blessie Elizabeth Nelson, MBBS, DMRT, The University of Texas MD Anderson Cancer Center, Houston, TX, the genomic profile of metaplastic breast cancer (MPBC) using data from the AACR GENIE Cohort...
3
3
7
@VJOncology @BlessieNelson @MDAndersonNews @AACR Congratulations @BlessieNelson I am so proud of you 👏🏼🙌🏻
0
1
1
Thanks to everyone who helped make my (almost) 1st year back in Colorado @CUCancerCenter extraordinary! ✨ Especially true for our #melanoma team! ✨ https://t.co/SYxB11Zb1X via @gotosage
news.cuanschutz.edu
When melanoma oncologist and clinical investigator Sapna Patel, MD, arrived at the CU Cancer Center last summer, she hit the ground running.
2
2
15
Deeply saddened that the entire team @NCICancerCtrl @theNCI PDQ Cancer Information has been eliminated. Our evidence-based summaries were updated throughout the year with the latest evidence and supported informed decision making between clinicians & patients across the US. 🇺🇸
6
35
67
Juicy #ASCO25 for ADC enthusiasts 👇
#ASCO25 is in 4 weeks Here all the oral presentations on ADCs (one table with all the topo1, the other one with all the non-topo1, mainly MMAE) Trends: more topo1, earlier lines, combo, new indications! Usual suspects: payloads and targets! (Posters will follow, stay tuned)
1
11
32
Happy weekend! ✈️ Tomorrow we're headed to the #HealthEquityCongress in Atlanta, where Megan Becker, the ED of our Winn CDA program, will be presenting this poster. Stop by and say hi! #BetterScienceForAll
0
3
6
👉Thanks 🙏 @chadinabhan for the personalized , autographed copy of his new book 📕 “The Cancer Journey” at #ThinkTank25 @sanamloghavi @VivekSubbiah @mpdrc @VincentRK @Rfonsi1 @drsangeetmd @CarrawayHetty @MikkaelSekeres @HimaglobinA @HannahGoulart @KrishPatelMD
1
6
35
Precision gene- and immune-targeted therapies show impressive results in metastatic solid cancers. Time to move to newly diagnosed disease as we did in CML— once a fatal leukemia, now near normal life expectancy 🎯💡🎯 https://t.co/30AprPueCe
1
7
27
#Myeloma Paper of the Day: CD56 expression modulates NAD+ metabolic landscape and may help predict sensitivity to anti-CD38 therapies & Isa-based regimens may provide comparable or even greater benefits than Dara-based regimens: https://t.co/eXkwA2anLB.
#mmsm
1
9
29
⭐️Efficacy of Hand Cooling and Compression in Preventing Taxane-Induced Neuropathy @JAMAOnc @JAMA_current
jamanetwork.com
This randomized clinical trial evaluates the efficacy of hand cooling and compression in reducing the risk of chemotherapy-induced peripheral neuropathy in patients with breast cancer.
1
3
16